A “wet chemistry” approach for isolation of At from an irradiated bismuth target is described. The approach involves five steps: (1) dissolution of bismuth target in conc. HNO3; (2) removal of the HNO3 by distillation; (3) dissolution of residue in 8 M HCl; (4) extraction of At from 8 M HCl into DIPE; and (5) extraction of At from DIPE into NaOH. Results from 55 “optimized” At isolation runs ga...

Treatment of micrometastases of HX34 human melanoma grown as xenografts in nude mice represents an advanced stage of preclinical investigations concerning targeted radiotherapy of this neoplasm using 3,7-(dimethylamino)phenazathionium chloride (méthylà ̈ne blue (MTB) labeled with astatine-211 (2"At) (a-particle emitter). The therapeutic effectiveness of 2"At-MTB administered i.v. was determined...

PURPOSE Technetium-99m (99mTc) has been widely used as an imaging agent but only recently has been considered for therapeutic applications. This study aims to analyze the potential use of 99mTc Auger electrons for targeted tumor radiotherapy by evaluating the DNA damage and its probability of correct repair and by studying the cellular kinetics, following 99mTc Auger electron irradiation in com...

The anti-ErbB2 antibody trastuzumab is used for the treatment of patients with advanced breast cancer, resulting in a response rate of 40-60%. Coupling with a cytotoxic nuclide, e.g. ·-emitting 211At, may further increase tumour response. The tumour-targeting properties of trastuzumab, astatinated using N-succinimidyl-para-(tri-nmethylstannyl)-benzoate, were evaluated and compared with those of...

ObjectivesDelta-like 1 homolog (DLK1) is a non-canonical Notch ligand known to be expressed in several cancers but whose role lung cancer not yet fully understood. We sought confirm DLK1 expression small-cell (SCLC) and non-small-cell (NSCLC), examine DLK1’s clinical significance. Furthermore, we examined the possible utility of as novel target radioimmunotherapy (RIT).MethodsWe retrospectively...